Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of BAX69 In Subjects With Malignant Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 Open-Label Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of BAX69 In Subjects With Malignant Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imalumab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Rectal cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; First in man
  • Sponsors Baxalta; Shire

    • Most Recent Events

    • 23 Mar 2020 Results assessing safety, tolerability, pharmacokinetics and antitumor activity of imalumab, an oxidized macrophage migration inhibitory factor inhibitor, in patients with advanced cancer, published in the British Journal of Clinical Pharmacology
    • 11 Oct 2016 Final results presented at the 41st European Society for Medical Oncology Congress (2016).
    • 13 Sep 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top